A Prospective, Phase IV, Surveillance Registry Study to Evaluate the Safety of DEFINITY® in Clinical Practice

Status:	Completed
Conditions:	Peripheral Vascular Disease
Therapuetic Areas:	Cardiology / Vascular Diseases
Healthy:	No
Age Range:	18 - Any
Updated:	4/21/2016
Start Date:	February 2008
End Date:	July 2009

CARES (Contrast EchocArdiography REgistry for Safety Surveillance): A Prospective, Phase IV, Open-Label, Nonrandomized, Multicenter, Surveillance Registry Study to Evaluate the Safety of DEFINITY® in Clinical Practice

The purpose of this registry study is to gather safety information on the current clinical
use of and the safety of DEFINITY®

Inclusion criteria

- Patients who, in the investigator's opinion, require DEFINITY® echocardiography due
to suboptimal, unenhanced images.

Exclusion criteria

- Known hypersensitivity to perflutren, DEFINITY®, or other echo contrast agent.

- Prior SAE associated with perflutren, DEFINITY®, or administration of other echo
contrast agent.

We found this trial at

sites

Wake Forest University Baptist Medical Center

1 Medical Center Blvd
Winston-Salem, North Carolina 27103

(336) 716-2011